Apollo Nears Deal for J&J’s Orthopedics Business in Potential $20 Billion Transaction
Private equity giant Apollo Global Management is in discussions to acquire Johnson & Johnson’s orthopedics division, DePuy Synthes, in a transaction that could value the unit at close to $20 billion, according to people familiar with the negotiations. If completed, the deal would rank among the largest healthcare private equity transactions of the year and mark a significant milestone in J&J’s ongoing effort to reshape its business portfolio.
People with knowledge of the discussions say the talks are private and that an agreement could be reached within several weeks, though they cautioned that negotiations could still end without a deal. Several other private equity firms have also expressed interest in the unit, meaning a rival bidder could yet emerge before any transaction is finalized.
A Business J&J Has Long Sought to Separate
DePuy Synthes manufactures hip, knee and shoulder implants, along with surgical instruments and related medical devices, and generated $9.3 billion in sales last year. J&J first signaled its intention to separate the unit roughly a year ago, announcing plans to spin off the business into a standalone company within 18 to 24 months as part of a broader strategy to concentrate resources on faster-growing segments of its healthcare portfolio.
The healthcare conglomerate’s chief financial officer has previously said the company was exploring multiple paths for the separation, with a tax-free spinoff to shareholders as the primary option, while remaining open to alternative structures such as an outright sale. Should the current negotiations with Apollo fall through, J&J retains the option of proceeding with a spinoff that would create the world’s largest standalone orthopedics company, according to the firm’s own estimates.
Why Apollo Is Interested
For Apollo, a deal of this size would represent its largest healthcare investment to date and would hand the firm control of a large medical-device business with established operations, a global customer base and steady recurring demand tied to aging populations and ongoing surgical volumes worldwide. Private equity investors have shown increasing appetite for healthcare assets with predictable cash flows this year, a trend illustrated by several other notable transactions across the sector.
Earlier this year, American Industrial Partners completed a 18 billion. Taken together, these deals point to a broader wave of private capital flowing into medical device and diagnostics companies as buyout firms search for stable, cash-generative businesses amid a more uncertain macroeconomic backdrop elsewhere.
What a Deal Would Mean for J&J’s Broader Strategy
A sale to Apollo would mark J&J’s second major divestiture in recent years as the company continues narrowing its focus toward higher-growth areas of pharmaceuticals and medical technology. The healthcare giant has been steadily reshaping its portfolio, and offloading a large but slower-growing device business like DePuy Synthes would free up management attention and capital for areas the company views as offering stronger long-term returns.
For DePuy Synthes itself, a change in ownership under Apollo could bring a different set of strategic priorities, including the operational discipline and capital allocation approach typical of private equity ownership, as opposed to the constraints of operating within a much larger, diversified public healthcare conglomerate.
What Investors Are Watching
Neither Apollo nor Johnson & Johnson has publicly commented on the discussions, and both companies declined requests for comment when the talks were first reported. Analysts covering the healthcare and private equity sectors say the coming weeks will be critical in determining whether Apollo can close out a deal at the reported valuation or whether a competing bidder emerges to drive the price higher.
For J&J shareholders, the outcome will offer an early signal of how successfully the company can execute its broader restructuring strategy, while for Apollo, closing the deal would cement its position as one of the most active private equity players in the global healthcare device market.
